AbbVie (NYSE: ABBV) is scheduled to report its earnings results for the second quarter of 2019 on Friday before the market opens.
What to expect from AbbVie Q2 earnings
Categories
pharmaceuticals
Earnings preview: Celgene deal in focus as Bristol-Myers prepares for Q2 results
Bristol-Myers Squibb (NYSE: BMY) will be releasing its quarterly results amid growing skepticism over the planned acquisition of rival drugmaker Celgene (CELG),
Earnings: Alexion Pharma Q2 results top expectations; raises FY19 guidance
Alexion Pharmaceuticals (Nasdaq: ALXN) reported a 28% growth for its second-quarter earnings, helped by an increase in revenues. The results also topped
These deals set a new paradigm for healthcare industry
After a busy 2018, the scale of merger and acquisition activity in the healthcare industry is expected to be high this year
Looming opioid epidemic calls for stricter drug regulation
Though the healthcare industry is slowly waking up to the hazards of opioid-based prescription drugs, their sale continues unabated across all markets,
Novartis’ one-time gene therapy for spinal muscular atrophy gets FDA nod
Picture Courtesy: Novartis Zolgensma, a gene-based treatment from Novartis (NYSE: NVS) for the treatment of spinal muscular atrophy that affects newborns, received
Earnings preview: Amarin likely to deliver strong Q4 results
Amarin Corporation (AMRN) is scheduled to report earnings results for the fourth quarter of 2018 on Wednesday, February 27, before the market
AbbVie slips to loss in Q4, misses estimates
AbbVie Inc. (ABBV) slipped to a loss in the fourth quarter from a profit last year, due to the inclusion of the
Arrowhead Pharmaceuticals reports a loss of 12 cents per share in Q4
Arrowhead Pharmaceuticals (ARWR) reported Q4 and fiscal 2018 earnings results after the bell today. For the fourth quarter ended September 30, 2018, the
Pfizer pares recent gains after JP Morgan slashes rating
The outlook for Pfizer (PFE) remains mixed as the drug maker gears up for a closely-followed leadership change early next year. While
Teva’s shares soar on better-than-expected Q3 results and higher guidance
Teva Pharmaceutical Industries Ltd. (TEVA) saw its stock gain over 6.8% during premarket hours on Thursday after the company surpassed expectations on
Humana beats on Medicare Advantage plans, raises outlook
Health insurer Humana (HUM) today reported its second-quarter earnings that surpassed analysts’ forecast, mainly due to surge in enrollment in the company’s
Is Johnson & Johnson a ‘sell’ in 2018?
Johnson & Johnson may not be having a great 2018 so far with the stock ticking down about 8% since the year